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SITE Study Appendix
Economic evaluation additional methods
Resource use
As discussed in the main paper, resource use was collected using the Child and Adolescent Service Use Schedule (CA-SUS). There is no single version of the CA-SUS, as it is adapted for the purpose of each different study. Therefore, any researchers considering using it, please contact Professor Sarah Byford for advice on the most appropriate version.
Unit costs
Unit costs for most health and social care services were obtained from the NHS Reference costs 2014/15 (Department of Health, 2015) and Unit Costs of Health and Social Care 2015 (Curtis and Burns, 2015) . Medications unit costs were estimated using an average cost per item from the Prescription Cost Analysis (Health and Social Care Information Centre, 2016) accounting for the reported number of days on that medication, and assuming the prescription lasted for one month. Pro re nata ("when necessary") medication were not included in the evaluation.
All unit costs applied in the economic evaluation, and the sources of these unit costs, are listed in Table 1 . Approach to missing data To explore the potential impact of excluding non-responders in the economic evaluation, we examined the socio-demographic and clinical characteristics of those included in the complete case analyses and those in the full sample. A secondary analysis was carried out with missing 6-month total costs and outcomes imputed using multiple imputations in Stata (version 14) and including baseline clinical and sociodemograhic variables.
Clinical evaluation additional results
Descriptive analysis of all outcomes, including number of patients with data, mean, SD, median, IQR and range, is reported in Table 1 . n/a n/a 24 18 (75.0%) n/a n/a 25 16 (64.0%) n/a n/a 29 15 (51.7%) n/a n/a
Full economic evaluation results
Follow-up and response rates
Of the 106 participants, 74% (78/106) had intervention, CA-SUS and outcome data, plus baseline variables to be controlled for in the regression analyses, thus allowing them to be included in the complete case cost-effectiveness analysis based on QALYs. This was 77% (82/106) for the costeffectiveness analysis based on the Children's Global Assessment Scale (CGAS). There were more SDS than TAU participants with complete data in both cost-effectiveness analyses (QALY based: 68% versus 79%; CGAS: 70% and 85%).
The mean follow-up time for participants with full data and able to be included in the costeffectiveness analyses was almost 7 months (range 5 to 14 months). This was slightly longer for the TAU arm with a mean follow-up of 231 days (71 days SD) compared with a mean of 199 days (31 days SD) in the SDS arm. This was a statistically significant difference (t=2.366, df=102, p=0.02) and is discussed in the main paper's discussion.
Service use
Data on service use between baseline and 6-month follow-up for the sample with a completed CA-SUS at 6-month follow-up are shown in Table 1 . Specialist supported discharge day patient services were used by 81% of the SDS group. The average number of weeks using the SDS was 11 (9 SD), with a range of 0-29 weeks. During the follow-up, almost all SDS and TAU participants spent time on hospital wards (100% SDS, 97% TAU). The mean number of days on an inpatient ward was 54 (SD 63) in the SDS arm and 88 in the TAU arm (SD 91). The percentage of participants using outpatient services was high (98% of the SDS arm and 92% of the TAU arm) as was the use of medication (82% of the SDS arm compared with 78% of the TAU arm) and the use of community services (78% of the SDS arm compared with 65% of the TAU arm). The use of A&E was similar between the two groups (42% in the SDS arm and 46% of the TAU arm) with the same mean of 1 use in both groups. Day patient services were used by few participants in each arm (7% in the SDS arm and 22% in the TAU arm) as was accommodation (11% in the SDS arm and 14% in the TAU arm). Accommodation used was mostly foster care (n6) with also some use of staffed accommodation (n3 staffed day and night; n1 staffed day only). Table 2 reports the total health and social care costs over the period from baseline to 6-month follow-up. The mean total cost of SDS day patient services was £24,150 per participant (SD £20,102, range £0 to £64,554). Other health and social care costs were significantly lower in the SDS arm by around £29,000 (95% CI -£53,647 to -£4,396, p=0.021). This was mostly due to the reduction in inpatient days experienced by the SDS group. In terms of total costs, the SDS group were cheaper than the TAU group (£63,621 versus £64,767), but this difference was not statistically significant (adjusted mean difference of -£3,675, 95% CI -£27,559 to £20,209, p=0.772). Results based on imputation for missing data were similar with no changes in terms of statistical significance. Outcomes Table 3 describes the EQ-5D and CGAS results at baseline and 6 months. At baseline, the SDS arm had lower EQ-5D based utility and CGAS scores although there was no statistical difference between the groups. EQ-5D based utility, EQ-5D based QALYs and CGAS scores were similar and there were no statistically significant differences between the groups at 6 months in terms of the observed data. However, the CGAS had a bigger increase in the SDS group. Results based on imputation for missing data were similar with no changes in terms of statistical significance. Due to concerns regarding overfitting given the relatively large number of pre-specified covariates in the cost-effectiveness regression analyses, we re-performed the adjusted analyses with a smaller number of co-variates hypothesised to have the greatest influence on cost-effectiveness -baseline CGAS, baseline EQ-5D based utility, inpatient days prior to randomisation and diagnosis. The additional analyses made little difference to the overall results and conclusions (adjusted ICER of the QALY of £101,500 versus £183,750 in the original analysis; adjusted ICER of the CGAS of £991 -the same as the original analysis). The cost-effectiveness acceptability curves for these were also almost identical to the original results. 
